摘要
TherearenotabledifferencesintheincidenceandmortalityratesforprostatecancerbetweenAsiaandWesterncountries.Itisalsorecognizedthattherearedifferencesinthinkingwithregardtotreatmentoptions.RecentlyitisalsothecasethatopinionshavebeenreportedconcerningthedifferencesbetweenAsianandWesternpatientswithregardtotheirreactiontoandrogendepletiontherapy(ADT).GiventhatADTisamethodoftreatmentthatfocusesontheeliminationoftestosterone,aninevitablesymptomofitsadministrationistestosteronelosingsyndrome.ItisforthisreasonthatinWesterncountriesADThasonlybeenrecommendedincasesofadvancedormetastaticcancer.Ontheotherhand,inAsia,ADTisusedinrelativelymanycases,includingnon-metastaticlocalizedcancerandinvasivelocalizedcancer.Todate,however,therehasbeenlittlesubstantivediscussionconcerningthisdifferenceinutilizationofADT.ADT-relateddrugsforprostatecancerandthedevelopmentofnewdrugsforcastrationresistantprostatecancer(CRPC)havebeenactivelytestedinrecentyears.ItcouldbethecasethatanalyzingthedifferencesinconceptsaboutADTbetweenAsiaandtheWestcouldcontributetotheeffectiveuseofADT-relateddrugsandalsohelptobuildnewtreatmentstrategiesforprostatecancer.
出版日期
2013年04月14日(中国期刊网平台首次上网日期,不代表论文的发表时间)